Systematic review of spontaneous reports of myocarditis and pericarditis in transplant recipients and immunocompromised patients following COVID-19 mRNA vaccination

Samantha Lane*

¹Drug Safety Research Unit, Southampton, UK

²School of Pharmacy & Biomedical Sciences, University of Portsmouth, UK

ORCID ID: 0000-0001-7532-1149

Alison Yeomans

¹Drug Safety Research Unit, Southampton, UK

Saad Shakir

¹Drug Safety Research Unit, Southampton, UK

²School of Pharmacy & Biomedical Sciences, University of Portsmouth, UK

*Correspondence to: Miss Samantha Lane

Drug Safety Research Unit, Bursledon Hall, Blundell Lane, Southampton, Hampshire, UK,
SO31 1AA

Samantha.Lane@dsru.org

Word count: 5098 (including subheadings and methods)

Number of tables: 4

Number of figures: 4

Abstract

Objectives: To determine whether spontaneous reporting rates of myocarditis and pericarditis differed in immunocompromised patients compared to the whole population overall, and in terms of demographics, vaccine dose, and time-to-onset.

Design: Systematic review of spontaneously reported data from the European Union/European Economic Area (EU/EEA), the United States (US) and the United Kingdom (UK).

Data Sources: EudraVigilance (EU/EEA), Vaccine Adverse Event Reporting System (VAERS; US) and the Medicines and Healthcare products Regulatory Agency (MRHA, UK) spontaneous reporting databases were searched from date of vaccine launch to 01 December 2021.

Eligibility criteria: Publicly available spontaneous reporting data for “Myocarditis” and “Pericarditis” from EU/EEA and US following COVID-19 mRNA vaccines. Reports with comorbidities or concurrent medication indicative of transplantation, HIV infection, or cancer (“immunocompromised” population) were compared with each overall database population.

Data extraction and synthesis: Two researchers extracted data. Spontaneously reported events of myocarditis and pericarditis were presented for immunocompromised populations for each data source, stratified by age, sex, dose, and time-to-onset (where available). Seriousness of each event was determined according to the ICH E2A definition. Proportional Reporting Ratio (PRR) was calculated.

Results: There were 178 reports of myocarditis and pericarditis amongst immunocompromised individuals overall. Seriousness was comparable between the immunocompromised and overall populations in both databases. No trends in age or sex were observed amongst immunocompromised individuals. Most reports followed a second vaccine dose and occurred within 14 days. The frequency of reporting was similar to the wider population (PRR=1.36 [95% CI= 0.89-1.82] for VAERS population).

Conclusions: Myocarditis and pericarditis following COVID-19 vaccination are very rare, and benefits of COVID-19 vaccination continue to outweigh any perceived risks. Reporting rates of myocarditis and pericarditis were similar in immunocompromised individuals, however defining characteristics differed compared to the whole population; therefore, continued monitoring of adverse events following vaccination remains vital to understand differences between population subgroups.

Strengths and Limitations of the Study

- This is the first study to investigate the frequency and characteristics of reported events of myocarditis and pericarditis in immunocompromised individuals compared with the population as a whole, bringing together data from three regions (Europe, the United States, and the United Kingdom).
- Results from this study demonstrate that myocarditis and pericarditis are not more frequently reported following COVID-19 mRNA vaccines for

immunocompromised individuals, however age and sex distributions are less clear, and clinical course may differ compared with the overall population.

- As with all analyses using spontaneously reported data, results may have been subject to underreporting and missing information, including information on comorbidities and concomitant medications. It is possible that some immunocompromised were incorrectly classified as immunocompetent. Further biases may have influenced results, including differences in vaccination strategies between the two regions examined, differences in data collected via spontaneous reporting systems, and serious events more likely to be reported.
- It is not possible to estimate incidence rates using spontaneous reports due to a lack of data on the exposed population, and there is no unexposed comparison group.
- Further monitoring of myocarditis and pericarditis events in immunocompromised populations is needed as booster vaccination programmes progress. Pharmacoepidemiological studies are urgently needed to provide more accurate estimates of the frequency and clinical course of myocarditis and pericarditis following COVID-19 mRNA vaccination amongst immunocompromised people.

Introduction

The COVID-19 mRNA vaccines developed by Pfizer BioNTech and Moderna were the first mRNA vaccines approved for use and have been successfully implemented in the fight against the COVID-19 pandemic (1-3). They are successful both in terms of efficacy of the vaccines to elicit a protective immune response as well as the speed of development; this methodology for vaccination likely enables rapid modifications to fight any potential variants that may evade the current vaccinations in the future. This success does not come without concerns though, and careful monitoring in real-world studies are essential to ensure these new mRNA vaccinations are safe across the whole population. It is also important to determine whether multiple dosing have any adverse effects especially if modified mRNA vaccinations may potential be used in the future to fight new variants or other viral infections.

Spontaneous reporting of adverse events enables a snapshot of real-world responses to be assessed, with the caveat that there is often under-reporting and missing data within these reports (4, 5). Reported adverse events that have been reported across the world in response to COVID-19 mRNA vaccinations and several have been recognised within the product information guidance, including myocarditis, pericarditis, and myopericarditis (6, 7). In Europe, myocarditis and pericarditis have been reported at an excess of 26 to 57 events per million within one week of COVID-19 mRNA vaccination, while in the US it has been estimated that these events are reported at a rate of between one and 40.6 cases per million second doses of COVID-19 mRNA vaccines administered (8, 9). Within these populations, reporting rates were dependent on sex and age, with males under 30 years of age reporting myocarditis and pericarditis following COVID-19 mRNA vaccines at a higher rate than females under 30 and people aged 30 years and over (8, 9). The incidence of myocarditis and pericarditis following COVID-19 mRNA vaccination is likely to be higher considering the well-known under-reporting of spontaneous adverse reactions. Myocarditis and pericarditis are caused by inflammation of the myocardium pericardium leading to chest pain, shortness of breath, palpitations, cardiac failure, or abnormal heart rhythms (10, 11). Myocarditis and pericarditis can occur without exposure to medications or vaccines, often induced by bacterial, viral, or fungal infections, and standard treatment includes, in addition to supportive therapy, anti-inflammatory medications such as colchicine and non-steroidal anti-inflammatory drugs (NSAID), corticosteroids, painkillers and as last resort pericardiocentesis to remove the excess fluid from around the heart (10, 11).

The mechanisms for myocarditis or pericarditis following COVID-19 mRNA vaccination are not yet fully understood. It has not yet been determined whether it is the mRNA element itself or the 'self' generated COVID-19 spike protein from the mRNA message within the vaccines or the resultant immune response, which cardiac tissues are sensitive to.

Following infection or vaccination, the adaptive immune system is activated. Adaptive immunity involves lymphocytes, particularly B-cells and certain T cells, that bind and recognise the foreign antigen. Upon first infection, or vaccination, the pathogen is bound by naïve B cells via the B cell receptor (BCR) or processed by antigen presenting cells (APCs) into smaller fragments, known as antigens. In order to mount an appropriate immune response, B cells will undergo differentiation and maturation within the lymph nodes in the germinal centre reaction (Figure 1). The germinal centre reaction results in

the generation of high affinity, high avidity BCRs for the antigen and leads to the production of antibody producing/secreting plasma B cells and memory B cells (Figure 1). Memory B cells will retain the ability to recognise this antigen after the infection has been cleared from the body and is able to rapidly produce plasma B cells and antibodies should the body encounter the pathogen again, rapidly eliminating a second challenge of infection. Simultaneously, T cells will undergo maturation in the thymus in the presence of foreign antigen presented by APCs and through the process of positive and negative selection results in deletion of T cells that bind with high avidity to 'self' molecules and promotes expansion of T cells that bind to the foreign antigen. This process of positive and negative selection also gives rise to immune tolerance where there is some cross-over in recognition of self-antigens (12). This immune-tolerance process may give rise to T cells that are reactive to self-antigens, in particular heart auto-reactivity (13), that could lead to myocarditis and pericarditis.

There are multiple hypotheses suggested by Das et al (14) that may explain the mechanism of myocarditis and pericarditis in response to the COVID-19 mRNA vaccines, including;

1. *"mRNA vaccines might generate very high antibody response producing a response similar to multisystem inflammatory syndrome in children (MIS-C) that is associated with COVID infection;*
2. *induction of anti-idiotypic cross-reactive antibody-mediated cytokine expression in the myocardium, resulting in aberrant apoptosis and inflammation,*
3. *mRNA vaccines can induce a non-specific innate immune response or a molecular mimicry mechanism may occur, or*
4. *the mRNA itself may be a potent immunogen producing an adjuvant effect."*

The advantage of mRNA vaccines is their ability to elicit a greater memory response compared to adenovirus vector vaccines (15). The longevity of mRNA vaccines (as evidenced by the persistence of the mRNA and mRNA translation APCs/dendritic cells (DCs) at the injection site and draining lymph nodes) for up to 10 days may enable fine-tuning of the immune responses due to somatic hypermutation, increasing the affinity of the BCR to the immunogen, as well as enabling memory B cell maturation (16) (Figure 1). The ability of mRNA vaccines to produce the immunogen of interest via mRNA translation from within APCs was thought to mimic viral infection, which would elicit a CD8+ cytotoxic T cell response but this is not seen with the COVID-19 mRNA vaccines or in mRNA vaccine trials against rabies virus glycoprotein (RABV-G) or Influenza (H1N1) (16). These mRNA vaccines have demonstrated that, in non-human primates, CD4+ helper T cell responses are elicited (17, 18).

The role of CD4+ T cells in myocarditis has been reviewed by Vdovenko and Eriksson that indicates that CD4+ T cells are the main drivers of heart-specific autoimmunity (19). Therefore, the CD4+ T cell response following mRNA vaccines may trigger myocarditis. CD4+ T cells differentiate into effector or regulatory T cells (T_{eff} or T_{reg} , respectively). T_{regs} are vital in immune tolerance to suppress autoimmune T_{eff} cells. Gender differences in circulating T_{regs} has been linked with gender differences in myocarditis (13). Thus the involvement in CD4+ T cells in myocarditis development may indicate that autoimmune responses may occur following mRNA vaccination, via induction of CD4+ T cell expression

and may point to the observed differences in myocarditis incidence between males and females following vaccination (20).

Whether the mRNA within the vaccine itself is immunogenic will likely depend on multiple variables within the mRNA sequence. The COVID-19 mRNA vaccines deliver a single stranded mRNA (ssRNA) encoding the spike protein, with modified nucleotides. The modified N¹-methyl-psuedouridine are known to dampen innate immune responses, while increasing the efficiency of translation *in vivo* (18). As ssRNA is produced by all cells within the body, ssRNA would be recognised as 'self' and would not trigger an immune response. Double-stranded RNA (dsRNA) is generally recognised by the cell as viral or is triggered for degradation via the RNA-induced silencing complex (RISC), the cells' innate ability to modify protein expression by degradation of mRNA (21). Thus the sequence of the ssRNA in the mRNA vaccine will determine the likelihood of complementarity (to itself, other mRNAs or microRNAs) to generate dsRNA which could then trigger immune responses via Toll-like Receptors (TLRs) (22) as well as alter mRNA translation mechanisms (21). Further investigation is needed to determine whether the mRNA sequence is complementary to any 'self' mRNA or microRNAs, as this could provide a greater understanding on why certain organs may be preferentially targeted in response to COVID-19 mRNA vaccination. The ability for mRNA vaccines to produce binding and neutralising antibodies in all participants in phase I/II trials (15) demonstrates the ability for these vaccines to activate the immune system similar to viral infection but with high antibody titres (23). Although it should be noted that immunocompromised individuals elicit a reduced antibody response following vaccination (24, 25). Thus, these highly immunogenic mRNA vaccines are activating the B and T lymphocytes, with the potential that heart-specific autoreactive CD4⁺ T cells may also be activated (or not adequately suppressed correctly via immune-tolerance interactions of T_{reg}'s with T_{eff} cells) potentially leading to reporting of myocarditis and pericarditis (4, 26, 27).

Immunosuppressant medications or conditions that lead to a compromised immune system inhibit the antigen presentation pathways alongside B and T lymphocyte signalling and maturation. This leads to our hypothesis that immunocompromised individuals might experience myocarditis or pericarditis at a higher frequency, that characteristics (age and sex) of immunocompromised patients reporting these events may differ, that clinical course may be more severe, and that duration of symptoms may be longer compared with immune competent individuals. We therefore aimed to determine the number of reports of myocarditis or pericarditis submitted by immunocompromised patient subgroups and whether these reports follow a similar reporting trend, in terms of age, sex, time-to-onset, and vaccine dose, compared with the population as a whole.

Materials and Methods

Systematic searches of spontaneous reporting outputs of the European Union/European Economic Area (EU/EEA; EudraVigilance) and the United States (US; Vaccine Adverse Event Reporting System [VAERS] via CDC Wonder tool) were conducted to obtain data on reported events of "myocarditis" and "pericarditis" amongst immunocompromised individuals following COVID-19 mRNA vaccination (COVID-19 Vaccines Pfizer/BioNTech

[Comirnaty] and Moderna [Spikevax]). Searches of the VAERS and EudraVigilance databases covered the period from the date of vaccine launch until 30 November 2021.

Meanwhile, systematic searches were carried out in the Yellow Card scheme's database of spontaneous reports to attain reports of myocarditis and pericarditis following mRNA vaccination for immunocompromised individuals. These searches were carried out by MHRA staff and supplied to us for analysis. The datalock point was 01 December 2021. Counts of overall reports of myocarditis and pericarditis were obtained within a personal communication from MHRA (datalock point 01 December 2021). Further details regarding the overall population fatalities were obtained from the 'Coronavirus vaccine - weekly summary of Yellow Card reporting' (28). The datalock point for this data was 08 December 2021.

For this analysis, immunocompromised individuals were defined as patients who were: transplant recipients, HIV/AIDS patients, or cancer patients using chemotherapies. Counts of myocarditis and pericarditis reports were tabulated for each immunocompromised subgroup. Denominators (the total number of vaccinees with these conditions) and the extent of missing data in these databases is unknown.

The level of detail within reports differs between spontaneous reporting databases depending on data collection forms used. In the VAERS database, it is possible to search for comorbidities, while in EudraVigilance it is necessary to use concomitant immunosuppressive treatments as a surrogate for immunosuppression. Therefore, in the VAERS database we searched for reports of myocarditis or pericarditis following at least one dose of COVID-19 mRNA vaccine (COVID-19 Vaccine Pfizer/BioNTech [Comirnaty] or COVID-19 Moderna [Spikevax]), where a history of transplantation, HIV/AIDS, or cancer was also reported. In both databases, searches were run for medications which could be used as a surrogate marker for transplantation, HIV/AIDS, or cancer; these medications included anti-rejection treatments, steroids, HIV/AIDS treatments, and anti-cancer therapeutics approved in the US and EU (29-31). Methotrexate was included as a medication proxy for transplant and cancer, however due to its wide use in autoimmune disease methotrexate was treated as a separate category. Age group and sex were obtained from each report and presented in a flowchart. Time-to-onset and vaccine dose were extracted, where these data were reported, and tabulated. Seriousness was obtained for each case, as defined in ICH Topic E2A: Clinical Safety Data Management, namely myocarditis and pericarditis events which were fatal, caused or prolonged hospitalisation (including surgery, where specified), or were life-threatening (32). Two researchers independently searched the spontaneous reporting databases and extracted data.

Proportional reporting rates (PRR) were calculated using the method described by Evans et al. (33). Briefly, a ratio of reports from myocarditis and pericarditis from immunocompromised subgroups were compared with the total myocarditis and pericarditis events from immune competent people following any dose of COVID-19 mRNA vaccination. PRR was calculated for the VAERS population only, due to limitations of the search functions available for the EudraVigilance dataset.

Considering that exposure to COVID-19 mRNA vaccines amongst immunocompromised individuals will continue to increase and that third and subsequent doses of the vaccines are likely to elicit stronger and longer lasting immune responses, this is intended to be a

“living” review of spontaneously reported data. We will provide an update when new information is released which significantly impacts our conclusions. At this time, systematic searches of spontaneous reporting databases using the above criteria will be run, and results and conclusions will be updated.

Patient and Public Involvement

Patients and the public were not consulted during this study due to the data source used. No identifiable information is included within the outputs of spontaneous reporting systems.

Results

European Union/European Economic Area

There were 49 individual cases of myocarditis or pericarditis submitted to EudraVigilance up to 30 November 2021 with EU/EEA origin, amongst patients with immunosuppression as suggested by concomitant medications. Myocarditis was detailed in 21 (42.9%) of the 49 total reports, while pericarditis was reported for 30 (61.2%) cases. There were two reports (4.1%) where both myocarditis and pericarditis were described. Most reports were from patients in the 18-64 years age group (61.2% of 49 reports); 91.8% of reports concerned adults aged 18 years or older (Figure 2). Twenty-eight of the 49 reports involved a male patient (57.1%; Figure 2). In total, 90 medications of interest were reported within the 49 cases submitted to EudraVigilance up to 30 November 2021 (Table 1). Of all concomitant medications investigated, cancer treatments were most commonly reported (n=50 of 90 medications, 55.6%; Table 1). Ciclosporin was least frequently reported (n=1, 1.1%; Table 1).

Of the 49 reports from immunocompromised individuals, 38 (77.6%) met the criteria for a ‘serious’ event (defined as: event caused or prolonged hospitalisation, was life threatening, or had a fatal outcome; Table 2). None of the myocarditis or pericarditis events reported in immunocompromised subgroups of interest up to 30 November 2021 had a fatal outcome. In contrast, 75.78% of myocarditis or pericarditis events reported to EudraVigilance in the population overall met the criteria for a serious case (n=4309 of 5681 cases reported following a COVID-19 mRNA vaccine, overall). Of these 5681 cases, 156 (2.7%) reported a fatal outcome.

United States

Meanwhile in the VAERS spontaneous reporting system, there was a total of 3,066 reports of myocarditis or pericarditis following mRNA vaccination (Pfizer or Moderna), of which 1.86% (n=57; Figure 3) were from immunocompromised individuals. These spontaneous reports of myocarditis or pericarditis in immunocompromised individuals differed in their gender and age distribution compared to the whole population with myocarditis or pericarditis (20). The whole population had a bias of younger males experiencing myocarditis or pericarditis following COVID-19 mRNA vaccinations (20), whereas from the immunocompromised population 52.6% of these events occurred in males and 50.9% were under 60 years of age. Thus, this could indicate a broadening in those susceptible to myocarditis or pericarditis in immunocompromised individuals. Splitting the analysis of immunocompromised individuals into transplant recipients,

medically induced immunosuppression using methotrexate, HIV, and cancer is indicated in Figure 3. Within these four subsets we investigated whether there were patterns in time-to-onset or vaccination dose for reported myocarditis or pericarditis events (Table 3). Predominately events were reported after the second mRNA vaccination (mean 54.4%; range 42.9 – 61.3% within immunocompromised subgroups), while 8.8% of events (range 0 – 16.1% within immunocompromised subgroups) were reported following the third vaccination dose (Table 3). Approximately 70% of reported events occurred within 14 days of vaccination (n=40; range 50 – 100% within immunocompromised subgroups; Table 3). Therefore, this is suggestive of a potential causal effect due to the rapid onset of symptoms following exposure to a COVID-19 mRNA vaccine. The seriousness of each event, (resulting in hospitalisation, surgery, or fatality) was assessed and recorded in Table 2, with 68.4% (n=39) of the 57 reports of myocarditis or pericarditis from immunocompromised subgroups meeting the criteria for ‘serious.’ Surgery was required for three individuals, and one fatality was recorded. The fatal event occurred in a female undergoing cancer therapy, eight days after receiving the first dose of COVID-19 Vaccine Moderna. Cause of death was not specified within the report, however an autopsy demonstrated systemic inflammatory reaction, which affected primarily the small blood vessels of the brain with leptomeninges, heart, lungs, and liver also affected. Generalised systemic tissue inflammation caused diffuse intravascular inflammatory microthrombi and haemorrhagic myocarditis. In comparison, for all myocarditis and pericarditis reports 63.4% were classified as serious, this includes immunocompromised as well as immune-competent individuals. Thus, we observed a slight increase (5%) in serious myocarditis or pericarditis in immunocompromised individuals compared to the overall population reporting via VAERS.

To determine whether these events were reported at higher levels in immunocompromised compared to immune-competent (or unspecified) individuals a PRR was calculated. This was only possible in the VAERS dataset, due to data limitations in the EudraVigilance dataset. In the VAERS population, the reporting rate of myocarditis and pericarditis was slightly higher for immunocompromised patients (transplant recipients, HIV/AIDS patients, and cancer patients) compared with immune competent individuals (PRR=1.36 [95% CI: 0.89-1.82]). However, no statistical differences were observed. Data on duration of symptoms was not available for either database examined.

United Kingdom

In total, 1009 reports of myocarditis and pericarditis following either COVID-19 mRNA vaccination had been submitted to the Yellow Card scheme up to 01 December 2021 (28). As of 08 December 2021, there had been three reported to have a fatal outcome; all three fatal events were in people who had received Comirnaty (28). The reporting rate for Comirnaty was 11 cases of myocarditis reported per million, and eight cases of pericarditis reported per million first or second vaccine doses. For Spikevax, there were 39 reports of myocarditis doses and 22 reports of pericarditis per million first and second doses of the vaccine administered (28). Reporting rates were highest for the 19-29 years age group for both COVID-19 mRNA vaccines, with a trend for decreased reporting in older age groups in the population overall (28).

Amongst immunocompromised individuals overall, there were 72 cases of myocarditis, pericarditis, or myopericarditis reported to the Yellow Card scheme up to 01 December 2021 (Figure 4). Therefore, of all myocarditis or pericarditis reports recorded in the UK,

7.1% were from immunocompromised individuals. The majority of myocarditis and pericarditis events were from people aged <65 years, similar to the overall population who had reported these events in the UK, whereas the male dominance of events seen in the whole population (74.9% of myocarditis and pericarditis were from males) (20) was not seen in the immunocompromised, here 51.4% of reports were from females (n=37; Figure 4). Further classification of these events reported in the UK are detailed in Table 4. One event was excluded from the analysis as it was not classified as myocarditis or pericarditis, rather it described general cardiac issues following COVID-19 mRNA vaccination.

Discussion and Conclusions

Based on the results of spontaneous reporting analyses, there was limited evidence supporting our hypotheses that frequency or seriousness of the myocarditis and pericarditis events reported to spontaneous reporting systems was substantially different for immunocompromised people compared with the population as a whole. In the overall database populations myocarditis and pericarditis seemed to more frequently affect younger males, however the characteristics of those susceptible may have broadened in the immunocompromised population in terms of age and sex; therefore, risk factors for these events are less clear within the immunocompromised population. Further pharmacoepidemiological research is warranted to quantify the incidence of myocarditis and pericarditis amongst immunocompromised patients compared with immune competent individuals, and to further characterise the risk factors for myocarditis and pericarditis following COVID-19 mRNA vaccination within each subpopulation.

Recent reporting of myocarditis and pericarditis in immunocompromised individuals (people on immunosuppressant medications following transplantation, treatment of cancer, or people with HIV infection) raises an important question into how the immune system is responding to mRNA vaccination in these individuals, and whether alternative COVID-19 vaccinations should be considered. Given the current understanding that COVID-19 mRNA vaccines elicit a CD4+ T cell response and the fact that immunocompromised patients have inhibited B and T lymphocyte activity, immune suppression could be a factor which increases the risk of adverse events following COVID-19 mRNA vaccination. In particular, myocarditis and pericarditis following COVID-19 mRNA vaccination may be due to the involvement of CD4+ T cells. Although HIV patients have demonstrated a similar immune response to vaccination compared with healthy adults, other immunocompromised patient subgroups, including those with solid or haematological cancers, solid organ or bone marrow transplantation, and other immunosuppressive conditions, have been shown to generate a lower immune response to COVID-19 vaccination compared with healthy controls (34-37). Therefore, it is possible that immunosuppression due to medication or a medical condition may have an impact on the safety and efficacy of mRNA vaccines against SARS-CoV-2 and other conditions.

Our analysis has not demonstrated a higher frequency of reports of myocarditis and pericarditis amongst the immunocompromised patient subgroups examined (PRR for the VAERS population=1.36 [95% CI: 0.89-1.82]), although the clinical course may be different for these patients compared with immune-competent individuals and requires

further monitoring. When the signal first emerged, myocarditis and pericarditis following COVID-19 mRNA vaccination were considered mild conditions of short duration which mostly affected younger males (20, 38-41). However, our analysis of reports from immunocompromised individuals resulted in this distinction being less apparent compared with that seen in the general population (20, 39, 40). Amongst immunocompromised individuals, males accounted for 52.6% of reported events of myocarditis and pericarditis submitted to all three datasets combined, thus a slight decrease in male predominance for this effect. Overall, 59.7% cases of myocarditis and pericarditis reported from immunocompromised individuals were under the age of 64 years. Furthermore, many of the reported events submitted to EudraVigilance and VAERS amongst immunocompromised subgroups met the criteria for a serious case (77.6% of 49 reports submitted to EudraVigilance, and 68.4% of 57 reports to VAERS). Meanwhile, 76.8% of myocarditis or pericarditis cases reported after COVID-19 mRNA vaccines to EudraVigilance from the population as a whole met the criteria for a serious case, while 63.4% of all cases reported to VAERS were serious in nature. For the US and UK population, time-to-onset was consistent with previous suggestions that these events occur within 14 days of vaccination, with approximately 66.4% of events reported to occur within 14 days of receiving a COVID-19 mRNA vaccine (38, 42). Consistencies in the frequency of events reported and the seriousness of cases for immunocompromised people within the data sources utilised suggests results may be generalisable to other populations in which mRNA vaccines are used. Interestingly, in comparison to the US data which demonstrated that 50% of events in immunocompromised occurred following the second dose of an mRNA vaccination, the UK data demonstrates a less apparent separation between doses one and two (31% vs 39.4%, respectively), while 23.9% of events occurred following the third dose.

Spontaneous adverse events reported to the Yellow Card scheme in the UK following a COVID-19 mRNA vaccination resulted in higher reporting of myocarditis and pericarditis in immunocompromised individuals as a proportion of the total myocarditis and pericarditis reports, compared to immunocompromised individuals in the EU and US databases (7.1% vs 0.84 and 1.86%, respectively). There are many potential reasons for these differences including different reporting systems that may allow for better collection of comorbidities or concomitant medication. It is possible that these data are underestimated, due to underreporting of events and missing information on comorbidities and concurrent medications within individual case reports (43). Spontaneously reported data from the population as a whole indicated myocarditis and pericarditis occurred predominately in young males. Results from the UK are consistent with those from the EU and US, where data demonstrated a broadening of these susceptible characteristics in immunocompromised individuals. Up to 15 December 2021, 38.4% of reports of myocarditis and pericarditis following COVID-19 mRNA vaccination were from females in the UK; therefore in the immunocompromised population there had been a 1.37-fold higher frequency of myocarditis and pericarditis reports from immunocompromised females (28). The majority of reports occurred following the second dose (39.4%) in the UK which was consistent with reports from the US (54.4% reported following a second dose), although this interpretation should be taken with caution given that the third dose (booster) programme is still ongoing in the UK, with more data likely to be reported in the coming weeks and months. However, immunocompromised people were prioritised to receive their third (booster) dose when

the UK booster vaccination programme started in September 2021, therefore it is expected that the majority of people within this subpopulation would have received their third dose by the datalock point of 01 December 2021 (44, 45).

In the data examined, indication for concomitant medication was not commonly reported; medications for cancer and HIV/AIDS may be used for other conditions and may therefore inaccurately represent the number of immunocompromised patients within the dataset. However, for the EudraVigilance population the use of a proxy measure was the only method for identifying reports from people in these patient subgroups. It is possible that these data are underestimated, due to underreporting of events and missing information on comorbidities and concurrent medications within individual case reports (5, 46). It will therefore become increasingly important to monitor the occurrence and clinical course of myocarditis and pericarditis amongst immunocompromised patients as booster vaccination programmes progress. While COVID-19 vaccination programmes continue to progress to widespread roll-out of third and subsequent booster doses, more immunocompromised individuals will become exposed to COVID-19 mRNA vaccines and some for the first time, particularly in countries where adenovirus vector COVID-19 vaccines were preferentially given to older members of the population and those at higher clinical risk of severe COVID-19 outcomes (many of whom were immunocompromised) for their first two doses. It should be noted that third vaccination doses, or boosters, are still in the early stages of dissemination, thus more informative data may be generated when a greater proportion of the total population have received a booster dose. Current data indicates that three doses of mRNA vaccines are safe, which included immunocompromised individuals in the population cohort (47).

Spontaneous reporting databases for the EU/EEA and US were selected for this analysis due to the high uptake of mRNA vaccines in these countries. In the UK, the mRNA vaccines were preferentially given to people under 40 years of age due to potential adverse effects of unusual blood clotting events with the COVID-19 AstraZeneca Vaccine in younger age groups; this may have caused bias in myocarditis and pericarditis reporting in younger males in the UK, earlier in the vaccination programme (48). Myocarditis and pericarditis following COVID-19 vaccination is not only restricted to the use of mRNA-based vaccinations. In the UK, 385 events of myocarditis and pericarditis had been reported via the Yellow Card scheme following administration of the AstraZeneca adenovirus vector COVID-19 vaccine, up to 15 December 2021 (28). Thus, monitoring of these events across all vaccination types may be required to determine if there are differences in reporting rates in immunocompromised individuals compared to the population as a whole within the UK. Further work is also required to determine whether there are any differences in the UK population compared to the EU and US populations that may account for the increased reporting of myocarditis and pericarditis in immunocompromised individuals in the UK.

Based on current data, immunocompromised individuals reporting myocarditis or pericarditis differed in gender and age distribution compared to the whole population. As risk factors for myocarditis and pericarditis are less clear in the immunocompromised population, it will be important to continue monitoring the occurrence and clinical course of myocarditis and pericarditis in immunocompromised individuals following COVID-19 mRNA vaccines. While there was a marginally higher proportion of myocarditis and pericarditis cases which met the criteria for 'serious' amongst immunocompromised

people compared with the overall population in both databases, the majority of events reported both from immunocompromised individuals and overall met the criteria for a serious event; this is possibly due to a higher likelihood that more severe cases are reported to the regulator. However, immunocompromised patients may be more aware of the adverse event reporting systems due to the nature and number of medications that they are prescribed, and thus may be more likely to submit a spontaneous report for a suspected adverse reaction to vaccination than immune competent individuals. Underreporting may be more likely for the general population for this reason, therefore may have biased the result; however, we do not know the extent of underreporting in either the immunocompromised or the overall population, so it is not possible to draw conclusions about this. Future analyses should consider the number of reports which are submitted by healthcare professionals versus patient-reported events. Therefore, careful and continued monitoring of the occurrence of these events is now needed. In addition, mRNA-based treatments and vaccines are in development for a number of diseases (including cancer, influenza, Zika virus, and HIV), some of which induce immunosuppression (49). Therefore, further monitoring of events in immunocompromised patients will be of particular importance if mRNA treatments and vaccines continue to be pursued for these conditions. If mRNA vaccines, and potentially other mRNA-based therapeutics, are linked with adverse events in immunocompromised individuals, this may alter their therapeutic potential, may alter treatment regimes, or may stratify patients into different treatment options. This strengthens the importance of further investigation and monitoring of this signal of myocarditis and pericarditis following COVID-19 mRNA vaccination in this subgroup. It is worth noting that autoimmune disorders, such as arthritis and systemic lupus, have been linked to pericarditis as well as some immunosuppressive medications, including methotrexate (50). Thus, careful evaluation needs to be undertaken, taking into consideration the baseline characteristics of this population to accurately determine the reporting rates related to mRNA vaccination.

It should be noted that our conclusions are based on the best available, though limited, information. Results should be confirmed by quantitative data, to allow accurate calculation of incident risk of myocarditis and pericarditis amongst immunocompromised patients compared with immune competent individuals. Further ongoing monitoring is needed to formally characterise the clinical course of myocarditis and pericarditis following mRNA vaccination amongst immunocompromised patients. It is important to stress that events of myocarditis and pericarditis following COVID-19 vaccination are very rare and the benefits of COVID-19 vaccination continue to outweigh any perceived risks.

References

1. FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine [press release]. 11 December 2020 2021.
2. UK authorises Pfizer/BioNTech COVID-19 vaccine [press release]. 2 December 2020 2020.
3. Dolgin E. The tangled history of mRNA vaccines. *Nature*. 2021;597(7876):318-24.
4. European Medicines Agency. EudraVigilance - European Database of Suspected Adverse Drug Reaction Reports. 2021.
5. Vaccine Adverse Event Reporting System. Guide to Interpreting VAERS Data 2021 [Available from: <https://vaers.hhs.gov/data/dataguide.html>].
6. BioNTech-Pfizer. Comirnaty concentrate for dispersion for injection COVID-19 mRNA Vaccine (nucleoside modified) 2021 [updated 22 July 2021. Available from: <https://www.medicines.org.uk/emc/product/12740/smpc>].
7. Medicines & Healthcare products Regulatory Agency. Summary of Product Characteristics for COVID-19 Vaccine Moderna 2021 [updated 25 June. Available from: <https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-moderna/information-for-healthcare-professionals-on-covid-19-vaccine-moderna>].
8. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 29 November - 2 December 2021 [press release]. 3 December 2021 2021.
9. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021. *MMWR Morbidity and mortality weekly report*. 2021;70(27):977-82.
10. British Heart Foundation. Myocarditis 2019 [updated December 2019. Available from: <https://www.bhf.org.uk/informationsupport/conditions/myocarditis>].
11. British Heart Foundation. Pericarditis 2019 [updated December 2019. Available from: <https://www.bhf.org.uk/informationsupport/conditions/pericarditis>].
12. Griesemer AD, Sorenson EC, Hardy MA. The role of the thymus in tolerance. *Transplantation*. 2010;90(5):465-74.
13. Vdovenko D, Eriksson U. Regulatory Role of CD4(+) T Cells in Myocarditis. *Journal of immunology research*. 2018;2018:4396351.
14. Das BB, Moskowitz WB, Taylor MB, Palmer A. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination: What Do We Know So Far? *Children (Basel, Switzerland)*. 2021;8(7).
15. Centers for Disease Control and Prevention. Science Brief: SARS-CoV-2 Infection-induced and Vaccine-induced Immunity 2021 [updated 29 October 2021. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/vaccine-induced-immunity.html>].
16. Cagigi A, Loré K. Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. *Vaccines (Basel)*. 2021;9(1).
17. Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. *N Engl J Med*. 2020;383(16):1544-55.
18. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. *Nature*. 2021;592(7853):283-9.
19. Vdovenko D, Eriksson U. Regulatory Role of CD4⁺ T Cells in Myocarditis. *Journal of Immunology Research*. 2018;2018:4396351.
20. Lane S, Yeomans A, Shakir S. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccines: A systematic review of spontaneously reported data from the UK, Europe, and the US and of the literature. *medRxiv*. 2021:2021.09.09.21263342.

21. Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. *Cell*. 2009;136(4):731-45.
22. Manik M, Singh RK. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. *Journal of medical virology*. 2021.
23. Walsh EE, Frenck RW, Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *The New England journal of medicine*. 2020;383(25):2439-50.
24. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients. *The New England journal of medicine*. 2021;385(7):661-2.
25. Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, et al. Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell*. 2021;39(8):1081-90 e2.
26. Golpour A, Patriki D, Hanson PJ, McManus B, Heidecker B. Epidemiological Impact of Myocarditis. *J Clin Med*. 2021;10(4):603.
27. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting 2021 [updated 19 November 2021. Available from: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>.
28. Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting 2021 [Available from: <https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting>.
29. National Cancer Institute. A to Z List of Cancer Drugs 2021 [Available from: <https://www.cancer.gov/about-cancer/treatment/drugs>.
30. Cancer Research UK. Cancer drugs A to Z list 2021 [Available from: <https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/drugs>.
31. NAM. HIV treatment A to Z of antiretroviral medications 2021 [Available from: <https://www.aidsmap.com/about-hiv/a-z-antiretroviral-medications>.
32. European Medicines Agency. ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. 1995 June. Report No.: CPMP/ICH/377/95.
33. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiology and Drug Safety*. 2001;10(6):483-6.
34. Sanders JF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. *Transplantation*. 2021.
35. Kearns P, Siebert, S., Willicombe, M., Gaskell, C., Kirkham, A., Pirrie, S., Bowden, S., Magwaro, S., Hughes, A., Lim, Z., Dimitriadis, S., Murray, S.M., Marjot, T., Win, Z., Irwin, S.L., Meacham, G., Richter, A.G., Kelleher, P., Satsangi, J., Miller, P., Rea, D., Cook, G., Turtle, L., Klenerman, P., Dunachie, S., Basu, N., de Silva, T.I., Thomas, D., Barnes, E., Goodyear, C.S., McInnes, I., . Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial. Available at SSRN: <https://ssrn.com/abstract=3910058> or <http://dx.doi.org/10.2139/ssrn.3910058>. 2021.

36. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. *Jama*. 2021;325(21):2204-6.
37. Rahav G, Lustig Y, Lavee J, Ohad B, Magen H, Hod T, et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. *EClinicalMedicine*. 2021;41.
38. Centers for Disease Prevention and Control. Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination 2021 [updated 12 November 2021. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>.
39. Woo W, Kim AY, Yon DK, Lee SW, Hwang J, Jacob L, et al. Clinical characteristics and prognostic factors of myocarditis associated with the mRNA COVID-19 vaccine. *Journal of medical virology*. 2021.
40. Li M, Yuan J, Lv G, Brown J, Jiang X, Lu ZK. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. *Journal of personalized medicine*. 2021;11(11).
41. Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. *The New England journal of medicine*. 2021.
42. Montgomery J, Ryan M, Engler R, Hoffman D, McClenathan B, Collins L, et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. *JAMA Cardiol*. 2021;6(10):1202-6.
43. García CH, Pinheiro L, Maciá MÁ, Stroe R, Georgescu A, Dondera R, et al. Spontaneous Adverse Drug Reactions [Available from: https://www.ema.europa.eu/en/documents/report/spontaneous-adverse-drug-reactions-subgroup-report_en.pdf.
44. NHS England. NHS begins COVID-19 booster vaccination campaign 2021 [updated 16 September 2021. Available from: <https://www.england.nhs.uk/2021/09/nhs-begins-covid-19-booster-vaccination-campaign/>.
45. Department of Health and Social Care. JCVI statement regarding a COVID-19 booster vaccine programme for winter 2021 to 2022 2021 [updated 14 September 2021. Available from: <https://www.gov.uk/government/publications/jcvi-statement-september-2021-covid-19-booster-vaccine-programme-for-winter-2021-to-2022/jcvi-statement-regarding-a-covid-19-booster-vaccine-programme-for-winter-2021-to-2022>.
46. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. *Drug safety*. 2006;29(5):385-96.
47. Niesen MJM, Pawlowski C, O'Horo JC, Challener DW, Silvert E, Donadio G, et al. Three doses of COVID-19 mRNA vaccination are safe based on adverse events reported in electronic health records. *medRxiv*. 2021:2021.11.05.21265961.
48. Mahase E. Covid-19: UK offers under 40s alternative to AstraZeneca vaccine to boost confidence. *BMJ (Clinical research ed)*. 2021;373:n1185.
49. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. *Nature Reviews Drug Discovery*. 2018;17(4):261-79.
50. Jastrzebska M, Czok ME, Guzik P. Autoimmune diseases, their pharmacological treatment and the cardiovascular system. *Cardiology journal*. 2013;20(6):569-76.

Table 1: Concomitant medications within spontaneous reports of myocarditis and pericarditis submitted to EudraVigilance for the European Union and European Economic Area only, following COVID-19 mRNA vaccines

Reports of myocarditis or pericarditis were searched in the EudraVigilance database following COVID-19 mRNA vaccines, either COVID-19 Vaccine Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty). Medications were used as a proxy for immunocompromised subgroups: transplant recipients (tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and steroids [including prednisolone]), HIV infection, and patients undergoing cancer treatment.

	Tacrolimus	Mycophenolate mofetil	Methotrexate	Ciclosporin	Prednisolone	HIV treatments	Cancer treatments**	Total*
Myocarditis	2	4	6	0	6	1	17	36
Pericarditis	0	2	8	1	9	1	33	54
Total*	2	6	14	1	15	2	50	90
*Reports may contain more than one concomitant medication, and/or more than one event								
**Hydrocortisone excluded as no indications given within reports and the drug is commonly used to treat other conditions								

Table 2: Breakdown of serious myocarditis and pericarditis events reported via EudraVigilance and VAERS

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, medicinal immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and Steroids, HIV or approved cancer therapeutics). Serious events were determined as required hospitalisation, surgery or fatality as detailed in the comments box. Values indicate the events recorded and in brackets the percentage of the total events in each of the four characteristic categories.

Immunocompromised Characteristic	Serious Events EudraVigilance*		Serious events VAERS		Total	
	n (%) [‡]	Total reported in subgroup	n (%) [‡]	Total reported in subgroup	n (%) [‡]	Total reported in subgroup
Transplant	22 (91.7)	24	2 (20.0)	10	24 (70.5)	34
Methotrexate-treated patients	11 (78.6)	14	5 (55.6)	9	16 (69.6)	23
HIV	2 (100.0)	2	3 (42.9)	7	5 (55.5)	9
Cancer Therapeutics	32 (65.3)	49	13 (41.9)	31	45 (53.8)	80
<p>*Counts not mutually exclusive, multiple medications could be reported in the same case</p> <p>[‡]Percentage of total reports within the EudraVigilance or VAERS database for that subgroup</p> <p>NB: Serious event defined as: event caused or prolonged hospitalisation, required surgery, was life threatening, or was fatal</p>						

Table 3: Spontaneous reports of myocarditis and pericarditis on the VAERS database following COVID-19 mRNA vaccines in immunocompromised individuals subdivided into time to onset and vaccine dosage

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer/BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, immunosuppressant drugs; tacrolimus, mycophenolate mofetil, methotrexate, Prednisolone, ciclosporin and Steroids, HIV or approved cancer therapeutics: <https://www.cancer.gov/about-cancer/treatment/drugs>). Values indicate the events recorded and as a percentage of the total in each of the four characteristic categories.

Reports to VAERS								
Immuno-compromised characteristic	Outcome		Vaccine dose				Time to Onset of Symptoms	
			Dose 1	Dose 2	Dose 3	Unknown dose	<14 days	>14 days
Transplant	Myocarditis	2 (20%)	0	2	0	0	0	2
	Pericarditis	6 (60%)	1	2	0	3	4	2
	Myopericarditis	2 (20%)	1	1	0	0	1	1
	Total	10 (100%)	2 (20%)	5 (50%)	0 (0.0%)	3 (30%)	5 (50%)	5 (50%)
Methotrexate	Myocarditis	0 (0%)	0	0	0	0	0	0
	Pericarditis	8 (88.9%)	4	4	0	0	6	1
	Myopericarditis	1 (11.1%)	0	0	0	1	1	0

	Total	9 (100%)	4 (44.4%)	4 (44.4%)	0 (0.0%)	1 (11.1%)	7 (77.7%)*	1 (11.1%)*
HIV	Myocarditis	2 (28.6%)	1	1	0	0	2 (28.6%)	0
	Pericarditis	4 (57.1%)	3	1	0	0	4 (57.1%)	0
	Myopericarditis	1 (14.3%)	0	1	0	0	1 (14.3%)	0
	Total	7 (100%)	4 (57.1%)	3 (42.9%)	0 (0.0%)	0 (0.0%)	7 (100%)	0 (0.0%)
Cancer Therapeutics	Myocarditis	10 (54.8%)	2	6	1	1	8	2
	Pericarditis	17 (32.3%)	4**	11	2	0	10**	7
	Myopericarditis	4 (12.9%)	0	2	2	0	3	0
	Total	31 (100%)	6 (19.4%)	19 (61.3%)	5 (16.1%)	1 (3.2%)	21 (67.7%)*	9 (29.0%)*
All	Total	57 (100%)*	16 (28.1%)	31 (54.4%)	5 (8.8%)	5 (8.8%)	40 (70.2%)	15 (26.3%)
* n=1, unspecified time to onset								
**n=1, fatality								

Table 4: Spontaneous reports of myocarditis and pericarditis submitted to the Yellow Card Scheme in the UK following COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis or pericarditis were searched in the Yellow Card scheme following COVID-19 mRNA vaccines, either COVID-19 Vaccine Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty). Events were classified by vaccination dose and time to onset of symptoms. *n=4 missing information on time-to onset, **n=1 excluded due to not classification by myocarditis, pericarditis or myopericarditis.

Reports to Yellow Card (UK)							
Outcome		Vaccine Dose				Time to Onset of Symptoms	
		Dose 1	Dose 2	Dose 3	unknown	<14 days	>14 days
Myocarditis	30 (42.3%)	13	11	5	1	19	8
Pericarditis	38 (53.5%)	9	14	12	3	24	13
Myopericarditis	3 (4.2%)	0	3	0	0	2	1
Total	71 (100%)**	22 (31.0%)	28 (39.4%)	17 (23.9%)	4 (5.6%)	45 (63.4%)*	22 (31.0%)*

Declarations

Transparency statement

The manuscript's guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported, and that no important aspects of the study have been omitted.

Ethics approval

Ethics approval was not required.

Funding

No external funding was received for the preparation of this manuscript.

Conflicts of interest

All authors have completed the Unified Competing Interest form (available on request from the corresponding author) and declare: The Drug Safety Research Unit (DSRU) is a registered independent charity (No. 327206) associated with the University of Portsmouth. The DSRU receives donations and grants from pharmaceutical companies; however, the companies have no control over the conduct or publication of its studies. The DSRU has received grants to conduct unconditional studies on the Oxford/AstraZeneca COVID-19 vaccine and is in negotiations to receiving grants for conducting CPRD studies for Pfizer, Moderna, and Janssen COVID-19 vaccines. The DSRU has conducted benefit-risk studies on products for COVID-19, including remdesivir, lopinavir/ritonavir, chloroquine and hydroxychloroquine, and convalescent plasma. Professor Shakir is the principal investigator for an active surveillance study for the Oxford/AstraZeneca vaccine, but this assessment is unrelated to this study. Professor Shakir has been a member of Data Safety Monitoring Boards for Ipsen, Biogen, and Diurnal. None of these companies have any involvement with COVID-19 vaccines. Professor Shakir was invited by AstraZeneca to advise on the events of thrombosis with thrombocytopenia with the COVID-19 vaccine and to be a member of an advisory committee on a safety study of the Oxford/AstraZeneca vaccine in Europe. Samantha Lane and Alison Yeomans have no conflicts of interest with regard to this study.

Authors' contributions

SL and AY were responsible for data acquisition, analyses, and interpretation. All authors were responsible for study conception, drafting and reviewing the manuscript, and approval of the final version for publication.

Data sharing

No additional data are available.

Figure 1: Schematic of the immune response to antigen

Antigen is part of a foreign/non-self pathogen and is presented by an antigen presenting cell (APC) either following viral protein digestion and presentation on the major histocompatibility complex (MHC) or via mRNA translation of the protein within the APC then the protein is presented on the MHC. The non-self protein presented on the MHC is recognised by B and T cells. This triggers a cascade of intracellular signalling responses and leads to the maturation of the B cells, within the germinal centre of a lymph node. The germinal centre reaction involves interactions with B cells, antigen and T cells; leading to somatic hypermutation of the B cell receptor (BCR), generating a BCR that is better adapted to recognise the antigen. The B cell then differentiates into memory B cells plasma B cells to release the antibodies into the general circulation to clear the body of the infection.

Figure 2: Tree diagram detailing the characteristics of vaccinees submitting spontaneous reports of myocarditis and pericarditis to EudraVigilance for EU and EEA only, following COVID-19 mRNA vaccines in immunocompromised individuals
 Reports of myocarditis or pericarditis were searched in the EudraVigilance database following COVID-19 mRNA vaccines, either Moderna (Spikevax) or Pfizer/BioNTech (Comirnaty) (N=48 reports). The resultant reports were further assessed for individuals that were likely to be immunosuppressed based on the following search terms (transplant medications*, HIV/AIDS treatments, EU-approved cancer therapies). Concomitant medications were used as a proxy for disease status.

†Counts are not mutually exclusive; one report may contain multiple concomitant medications from different categories.
 *Where tacrolimus, mycophenolate mofetil, ciclosporin, or prednisolone were reported as concomitant medications.
 **Methotrexate was included as a potential transplant medication, however due to its wide use in autoimmune disease this was listed independently of the treatments used as a proxy for transplantation.

Figure 3: Tree diagram detailing the characteristics of spontaneous reports of myocarditis and pericarditis on the VAERS database following COVID-19 mRNA vaccines in immunocompromised individuals

Reports of myocarditis, pericarditis or myopericarditis were searched in the VAERS database following COVID-19 mRNA vaccines, either Moderna or Pfizer BioNTech. The resultant reports were further assessed for individuals that were likely to be immunocompromised based on the following search terms (transplant, tacrolimus, mycophenolate mofetil, methotrexate, prednisolone, ciclosporin). Transplant recipients were assessed separately to immunocompromised individuals that received medication, independent of disease setting.

* unspecified category , ** cancer defined by use of cancer approved medicines

Figure 4: Tree diagram detailing the characteristics of spontaneous reports of myocarditis and pericarditis on the Yellow Card database following COVID-19 mRNA vaccines in immunocompromised individuals (Yellow Card, UK)

Reports of myocarditis, pericarditis or myopericarditis from immunocompromised individuals were searched in the Yellow Card scheme following COVID-19 mRNA vaccines, either Moderna or Pfizer BioNTech. Data provided by MRHA, datalock 1st December 2021. * n=3 unspecified, ** n=2 under 18 years. For age category n=5 unknown.